Complement is a central mediator of radiotherapy-induced tumor-specific immunity and clinical response

补体是放射治疗引起的肿瘤特异性免疫和临床反应的中心介质

阅读:6
作者:Laura Surace, Veronika Lysenko, Andrea Orlando Fontana, Virginia Cecconi, Hans Janssen, Antonela Bicvic, Michal Okoniewski, Martin Pruschy, Reinhard Dummer, Jacques Neefjes, Alexander Knuth, Anurag Gupta, Maries van den Broek

Abstract

Radiotherapy induces DNA damage and cell death, but recent data suggest that concomitant immune stimulation is an integral part of the therapeutic action of ionizing radiation. It is poorly understood how radiotherapy supports tumor-specific immunity. Here we report that radiotherapy induced tumor cell death and transiently activated complement both in murine and human tumors. The local production of pro-inflammatory anaphylatoxins C3a and C5a was crucial to the tumor response to radiotherapy and concomitant stimulation of tumor-specific immunity. Dexamethasone, a drug frequently given during radiotherapy, limited complement activation and the anti-tumor effects of the immune system. Overall, our findings indicate that anaphylatoxins are key players in radiotherapy-induced tumor-specific immunity and the ensuing clinical responses.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。